Tumour Hypoxia — Why Oxygen Matters in Radiation Treatment

Oxygen decides whether radiation damage sticks. Radiation splits water inside a cell into unstable molecules that break the DNA, and oxygen then locks those breaks in place so the cell cannot simply repair them. Cells sitting in a poorly oxygenated pocket of a tumour can need roughly two to three times more dose for the same effect.

It helps to know that radiation mostly does not hit the DNA directly. Cells are largely water, so a beam is far more likely to strike a water molecule than the DNA strand itself. That collision produces short-lived, highly reactive fragments, and those fragments are what tear into the DNA nearby. This is called the indirect effect, and it accounts for the large majority of the damage from the beams used in everyday radiotherapy.

Oxygen enters at the next step. A DNA break made by one of those fragments is chemically unstable for a moment: it can either be repaired back to normal, or it can react with oxygen and become fixed. Fixed damage is what the cell struggles to undo. With plenty of oxygen present, more of the damage becomes permanent. With very little oxygen, more of it is quietly repaired before the next session. Radiobiologists call this the oxygen effect, and the size of it is one of the most reproducible findings in the field: it takes on the order of two to three times more dose to achieve the same effect in a severely oxygen-starved cell as in a well-oxygenated one, a figure taught in ASTRO- and NCCN-aligned curricula and current as of August 2026.

Now put that inside a real tumour. Tumours grow faster than the blood vessels that supply them, and the vessels they do build are often leaky, twisted and unreliable. Oxygen can only diffuse a very short distance from a working capillary before it runs out. So the rim of a tumour, close to the blood supply, is well oxygenated and behaves as the textbook predicts — while the centre can be genuinely starved. That is tumour hypoxia. It is not a defect in you or in your treatment; it is a normal consequence of how tumours grow.

Your radiotherapy is delivered at an NABH-accredited partner centre; CION Cancer Clinics coordinates your treatment plan, your oncology team and your care throughout, so the reasoning behind your dose and schedule is explained to you rather than simply handed over.

It can matter, and your team checks it. Haemoglobin is what carries oxygen from your lungs to the tumour, so a low level means less oxygen reaching tissue that is already short of it. Observational studies in cervical and head-and-neck cancers have reported an association between low haemoglobin during radiotherapy and poorer local control.

The logic follows directly from the mechanism above. If oxygen is what makes radiation damage permanent, then anything that reduces the oxygen arriving in the tumour bed is worth knowing about. Haemoglobin, carried in your red blood cells, is the vehicle for almost all of it. When haemoglobin falls, the amount of oxygen delivered per unit of blood falls with it, and the poorly supplied centre of a tumour is the first place to feel that.

Two honest cautions belong here. First, this is an association reported in observational research, not a promise: nobody can tell you that a particular haemoglobin number will change your individual outcome. Second, and more practically, correcting anaemia is not a simple good in itself. The available options each carry their own risks and their own eligibility rules, and guideline bodies including NCCN are deliberately cautious about how and when anaemia is corrected during cancer treatment. This is precisely why this page will not tell you what to take. Naming a treatment for your blood count would be irresponsible from a website that has never seen your reports.

What is reasonable to expect is that the question gets asked. Anaemia is common in people with cancer — from the disease itself, from bleeding, from nutrition, from other treatment — and it is part of routine supportive-care assessment before and during a radiation course. If you feel unusually breathless on stairs, persistently exhausted, dizzy on standing, or you look paler than usual, say so at your next review rather than filing it under “treatment is tiring”. It is a symptom worth naming, not a complaint.

This section explains a concept so that you can ask better questions. It is not treatment advice, and no decision about your blood count should be made from it.

Yes, and the oxygen link is direct. One of the gases in tobacco smoke binds to haemoglobin far more tightly than oxygen does, so fewer of your red blood cells are actually carrying oxygen while you smoke. Smoke also narrows small blood vessels, which reduces the flow reaching the tumour bed.

Think of it as two hits on the same system. The first is chemical: a portion of your haemoglobin is occupied by something that is not oxygen, so the carrying capacity of your blood drops even when your haemoglobin count on paper looks fine. The second is circulatory: smoke constricts small vessels, so less blood arrives where it is needed. Both effects pull in exactly the wrong direction for a tumour whose centre is already oxygen-starved.

There is more to it than the beam. People who continue smoking through a radiation course tend to report more trouble with the skin in the treated area, and more mucosal soreness where the mouth, throat or gullet sits in the field — the tissues that need good blood flow to recover between sessions are the same ones smoke compromises. Recovery afterwards is often slower for the same reason.

Both NCCN, through its supportive-care guidance, and the WHO treat stopping smoking as part of cancer care rather than a lifestyle footnote, and current guidance is clear that it is worth doing at any stage, including after a diagnosis and mid-course. That is stated here as what the guideline bodies say, not as a lecture. Nobody who has been smoking for thirty years stops because a website told them to. What is worth knowing is that quitting support is a normal, non-judgemental part of an oncology service — you can ask for it in the same breath as asking about your skin cream, and it works better than willpower alone.

If you smoke, tell your radiation oncologist plainly rather than under-reporting it. It changes how they read your side effects and what support they offer — it will not change how you are treated as a person.

The same beam, the same dose and the same tumour can produce very different results millimetres apart. The difference is how far that piece of tissue sits from a working blood vessel, and therefore how much oxygen is present at the moment the DNA break is made.

This is a teaching comparison, not a map of your own tumour. Where hypoxia sits in your case, and how much it matters, is a question for your radiation oncologist with your imaging in front of them.

In practice, yes — without the word ever being used. Fractionating a course over weeks, treating a margin wider than the visible tumour, and reviewing your blood counts along the way are all responses to the oxygen problem, built into standard practice long before anyone reaches your particular case.

That is worth knowing because hypoxia is easy to read about and then worry about privately. Nobody routinely measures oxygen inside a tumour in day-to-day practice: it takes either a probe placed into the tissue or specialised imaging that remains largely a research and specialist-centre tool. What your radiation oncologist works with instead are the proxies — how bulky the tumour is, what its blood supply looks like on imaging, what your haemoglobin is doing, and whether you smoke. Those already shape the dose, the margins and the schedule on your plan.

If you are gathering a second opinion, this is a fair thing to raise, and it tells you something about the consultation you are getting. A useful second opinion re-reads the imaging and pathology rather than the summary letter, explains why the total dose and the number of sessions were chosen, checks what the organs beside the tumour can tolerate, and asks about the supportive-care side — blood counts, smoking, nutrition — rather than treating the beam as the whole story. It may well confirm the original plan. That is a useful outcome, not a wasted appointment.

At CION Cancer Clinics a written second opinion from a radiation oncologist is offered free, with no commitment to change or start treatment anywhere. Radiotherapy itself is delivered at an NABH-accredited partner centre, with CION coordinating your plan, your team and your care throughout.

• Hypoxia is one of several reasons a tumour can respond less than expected — Why Some Tumours Do Not Respond Well to Radiation sets it alongside DNA repair, tumour bulk and cell type.
• Wondering how the total dose on your plan sheet was arrived at, and where the oxygen problem fits into that arithmetic? What Decides the Total Radiation Dose You Receive walks through the factors being balanced.
• The graph your team uses to check how much dose lands on the tumour versus everything around it is explained in What Is a DVH (Dose Volume Histogram)? — useful if your plan review is coming up.
• Because the safe limit for the tissue next door often caps what the tumour can receive, Organs at Risk and Dose Constraints: What Your Plan Protects is the natural companion to this page.
• For the wider picture — how radiation is planned, delivered and coordinated with NABH-accredited partner centres — see Radiation Therapy at CION Cancer Clinics.

Still want this connected to your own diagnosis? Book a free consultation and a radiation oncologist will go through your reports with you directly.